EUVIMEDAtrasti EUVIMED
BeobachtungsstudieOpen access · CC BY 4.0

Cost‐Effectiveness of Preemptive Plerixafor Versus Rescue Plerixafor for Mobilization and Collection of Hematopoietic Stem Cells in Patients With Multiple Myeloma and Lymphoma

Kosteneffektivität von präemptivem Plerixafor versus Rescue-Plerixafor zur Mobilisierung und Sammlung hämatopoetischer Stammzellen bei Patient:innen mit Multiplem Myelom und Lymphom

Roselene Mesquita Augusto Passos iD, Miriam Allein Zago Marcolino iD, Júlia Augusto Passos iD, Vinicius Fernando Calsavara iD, Leila de Lourdes Martins Perobelli iD, Alessandro Gonçalves Campolina iD, Cesar de Almeida-Neto iD

Journal of Clinical Apheresis · 2025-06 · 40 (3)

DOI: 10.1002/jca.70026 ↗

Auf einen Blick

Bei 285 Patient:innen war präemptives Plerixafor mit weniger Mobilisationsversagen und mehr ASCT-Verläufen verbunden als Rescue-Plerixafor. Die Kosten waren höher, die Kosteneffektivität blieb laut Autoren günstig.

Fragestellung

Ist präemptives Plerixafor im Vergleich zu Rescue-Plerixafor bei Patient:innen mit Multiplem Myelom oder Lymphom kosteneffektiver?

Methode

Beobachtungsstudie im brasilianischen öffentlichen Gesundheitssystem; Vergleich präemptiv vs. Rescue-Plerixafor; Auswertung von Kosten und klinischen Outcomes.

Ergebnisse

285 Patient:innen: 82 präemptiv, 203 Rescue. Inkrementelle Kosten US$ 1532.44. Inkrementelle Wirksamkeit: 10.1 % bei minimal erfolgreicher Sammlung (ICER US$ 151.28), 4.7 % bei optimaler Sammlung (ICER US$ 326.05), 13.1 % bei ASCT (ICER US$ 116.18).

Schlussfolgerung der Autor:innen

Präemptives Plerixafor ist laut Autoren eine kosteneffektive Strategie gegenüber Rescue-Plerixafor, mit höherer Wirksamkeit und klinischem Nutzen trotz höherer Kosten.

Kernaussagen

  • Weniger Mobilisationsversagen unter präemptivem Plerixafor
  • Mehr Patient:innen erreichten eine ASCT
  • Für Leukapherese-Sitzungen war präemptives Plerixafor dominiert

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Beobachtungsstudie in Journal of Clinical Apheresis, published online on 2025-05-03. Written by Roselene Mesquita Augusto Passos and 6 co-authors. Institution: Departamento de Transplante de Medula Óssea e Hematologia, Hospital de Transplantes Euryclides de Jesus Zerbini, São Paulo, Brazil. Major MEDLINE topics: Multiple Myeloma, Hematopoietic Stem Cell Mobilization, Lymphoma, Heterocyclic Compounds. Cited 3 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY 4.0). Funded by: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brazil (CAPES), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

Auf einen BlickSantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Background

Plerixafor combined with granulocyte colony‐stimulating factor (G‐CSF) has shown superior efficacy in mobilizing hematopoietic stem cells (HSCs). However, its widespread use is constrained by high costs, and there is ongoing debate regarding the effectiveness of mobilization strategies. This study evaluated the cost‐effectiveness of preemptive versus rescue plerixafor in patients from the Brazilian Public Health Care System with multiple myeloma or lymphoma eligible for autologous stem cell transplantation (ASCT).

Methods

This observational study assessed the costs and clinical outcomes of preemptive and rescue plerixafor strategies. The incremental cost‐effectiveness ratio (ICER) was calculated for the percentage of patients with successful optimal or minimal HSC collections, who underwent ASCT and the number of leukapheresis sessions.

Results

The study included 285 patients, 82 in the preemptive and 203 in the rescue group. Preemptive plerixafor resulted in a lower mobilization failure rate, a decreased need for remobilization, a higher proportion of patients progressing to ASCT, and a shorter interval between the beginning of mobilization and ASCT. The incremental cost of preemptive versus rescue plerixafor was US$ 1532.44. The incremental effectiveness observed was 10.1% for minimally successful harvest (ICER US$ 151.28), 4.7% for optimal harvest (ICER US$ 326.05), and 13.1% for patients progressing to ASCT (ICER US$ 116.18). Regarding the number of leukapheresis sessions, preemptive plerixafor was dominated. Summary Preemptive plerixafor is a cost‐effective strategy compared to rescue plerixafor, offering higher efficacy and lower ICER values, making it a clinically beneficial option despite its higher cost.

Subjects

MeSH terms (MEDLINE)

Multiple MyelomaHematopoietic Stem Cell MobilizationLymphomaHeterocyclic CompoundsHumansCyclamsBenzylaminesCost-Benefit AnalysisMiddle AgedFemaleMaleAdultTransplantation, AutologousAgedHematopoietic Stem Cell TransplantationGranulocyte Colony-Stimulating FactorHematopoietic Stem Cells

Author keywords

AMD3100autologous transplantationcost effectiveness ratiogranulocyte colony‐ stimulating factorleukapheresis

Substances

plerixaforCyclamsBenzylaminesHeterocyclic CompoundsGranulocyte Colony-Stimulating Factor

Authors and institutions

  • Departamento de Transplante de Medula Óssea e Hematologia, Hospital de Transplantes Euryclides de Jesus Zerbini, São Paulo, Brazil.
  • Programa de Pós-Graduação em Ciências Médicas da Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
  • Programa de Pós-Graduação em Epidemiologia, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
  • Instituto para Avaliação de Tecnologia Em Saúde -INCT/IATS (CNPQ 465518/2014-1), Universidade Federal do Rio Grande do Sul, Rio Grande do Sul, Brazil.
  • Faculdade de Medicina de Jundiaí, São Paulo, Brazil.
  • Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.

ORCID profiles: Roselene Mesquita Augusto Passos, Miriam Allein Zago Marcolino, Júlia Augusto Passos, Vinicius Fernando Calsavara, Leila de Lourdes Martins Perobelli, Alessandro Gonçalves Campolina, Cesar de Almeida-Neto

Funding

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brazil (CAPES)
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Cite

APA

Passos, R. M. A., Marcolino, M. A. Z., Passos, J. A., Calsavara, V. F., de Lourdes Martins Perobelli, L., Campolina, A. G., & de Almeida-Neto, C. (2025). Cost‐Effectiveness of Preemptive Plerixafor Versus Rescue Plerixafor for Mobilization and Collection of Hematopoietic Stem Cells in Patients With Multiple Myeloma and Lymphoma. Journal of Clinical Apheresis, 40(3). https://doi.org/10.1002/jca.70026

Vancouver

Passos RMA, Marcolino MAZ, Passos JA, Calsavara VF, de Lourdes Martins Perobelli L, Campolina AG, et al. Cost‐Effectiveness of Preemptive Plerixafor Versus Rescue Plerixafor for Mobilization and Collection of Hematopoietic Stem Cells in Patients With Multiple Myeloma and Lymphoma. Journal of Clinical Apheresis. 2025;40(3). doi:10.1002/jca.70026

BibTeX
@article{Passos2025,
  author = {Passos, Roselene Mesquita Augusto and Marcolino, Miriam Allein Zago and Passos, Júlia Augusto and Calsavara, Vinicius Fernando and de Lourdes Martins Perobelli, Leila and Campolina, Alessandro Gonçalves and de Almeida-Neto, Cesar},
  title = {Cost‐Effectiveness of Preemptive Plerixafor Versus Rescue Plerixafor for Mobilization and Collection of Hematopoietic Stem Cells in Patients With Multiple Myeloma and Lymphoma},
  journal = {Journal of Clinical Apheresis},
  year = {2025},
  volume = {40},
  number = {3},
  doi = {10.1002/jca.70026}
}
Start for free →